Loading...
Loading...
1 min read
Researchers take the first step in developing a drug treatment that mimics the effects of physical rehabilitation, restoring motor function in animal models. This breakthrough could transform the therapeutic approach for millions of patients.est
Neurology is experiencing a historic moment thanks to the work of researchers at the University of California, Los Angeles (UCLA), who have discovered what could become the first drug treatment capable of replicating the effects of physical rehabilitation after a stroke.
In the study, two experimental drugs were evaluated for their ability to mimic the neurological benefits of rehabilitation. One of them, DDL-920, demonstrated a remarkable ability to restore motor function in mice affected by stroke, opening up the possibility of radically transforming recovery prospects for millions of patients who currently face lengthy therapies with limited results.
The mechanism of action of this treatment represents a significant breakthrough in our understanding of neurological recovery. Research revealed that stroke disrupts a key process for motor function: communication between parvalbumin neurons, which are essential for movement coordination as they synchronize different brain areas through gamma oscillations. Administration of DDL-920 successfully restored these oscillations and promoted the reconnection of damaged neural circuits.
The magnitude of this discovery becomes even more relevant when considering that stroke affects nearly 15 million people worldwide each year, of whom only 10% fully regain their mobility (1). Moreover, many patients abandon rehabilitation due to its intensity and high cost.
Currently, there are no available drugs that directly target post-stroke rehabilitation, leaving patients entirely reliant on physical therapies, which are not always sustainable or accessible for everyone. In this context, the development of a pharmacological treatment offers an alternative that could complement—or even replace—traditional rehabilitation.
While the results in animal models are promising, human application still requires further research. Clinical trials will be necessary to assess the drug’s safety and effectiveness before it can be considered for clinical use. In parallel, studies are already underway to optimize its formulation and minimize potential side effects.
This discovery marks a decisive breakthrough in neurological recovery research, opening the door to therapies that directly stimulate the brain’s natural plasticity mechanisms, with the potential to transform not only stroke treatment but also other neurological conditions associated with mobility loss.